A Phase 4 interventional study of Testosterone cypionate (200mg/3ml) and Sesame oil (3ml) in Weaning Failure, Muscle Weakness and Mechanical Ventilation Complication, sponsored by Leticia Maria Defendi Barboza Marson. Active, not recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by Leticia Maria Defendi Barboza Marson · Phase 4, Interventional, and Supportive care
The objective of this study is to evaluate whether the use of the anabolic agent testosterone cypionate in critically ill patients, compared to placebo, increases the number of ventilator-free days
It will be a randomized, controlled, double-blind, single-center clinical trial conducted in the Intensive Care Unit (ICU) of the State Hospital of Serrana (HE Serrana). Patients admitted to the ICU who meet the eligibility criteria and have given written informed consent will be randomized into control and intervention groups. Forty-seven patients will be included in each group, totaling 94 patients. The intervention group will receive 200 mg of testosterone cypionate intramuscularly every 5 days for a total of 3 doses. The control group will receive a placebo on the same schedule. After inclusion in the study, demographic and clinical data, laboratory results, ultrasonographic measurements, and functionality and muscle strength scores will be assessed on days 1, 5, 10, and 15 in the ICU and until hospital discharge.
Exclusion Criteria:
Participants will receive 200 mg of testosterone cypionate intramuscularly every 5 days, up to a maximum of 3 doses.
Drug: Testosterone cypionate (200mg/3ml)
Participants will receive sesame oil (placebo) intramuscularly every 5 days, up to a maximum of 3 doses.
Other: Sesame oil (3ml)
It will be administered intramuscularly every 5 days, totaling 3 doses.
It will be administered intramuscularly every 5 days, totaling 3 doses.
Ventilator-free days at 28 days, starting from the date of randomization.
Evaluate whether the use of the anabolic steroid testosterone cypionate, compared to a placebo, increases the number of ventilator-free days in critically ill patients.
Time frame: 28 days
Length of stay in the hospital, measured in days.
Evaluate the effects of testosterone cypionate use on the length of hospital stays.
Time frame: ICU and hospital stay, assessed up to 8 weeks.
Length of stay in the ICU, measured in days.
Evaluate the effects of testosterone cypionate use on the length of ICU (Intensive Care Unit) stays.
Time frame: ICU and hospital stay, assessed up to 8 weeks.
Ventilator weaning time in days, starting from the date of randomization.
Evaluate the effects of testosterone cypionate use on the duration of mechanical ventilation.
Time frame: ICU stay, assessed up to 8 weeks.
In-hospital mortality from any cause.
Evaluate the effects of testosterone cypionate use on in-hospital mortality.
Time frame: Hospital stay, assessed up to 8 weeks.
Sequential Organ Failure Assessment (SOFA) score during the ICU stay, starting from the date of randomization.
Evaluate the effects of using testosterone cypionate on the SOFA score during ICU hospitalization. This score is used to assess the degree of organ dysfunction in the patient, with scores ranging from 0 to 24 points; the higher the score, the greater the severity and risk of mortality in critically ill patients.
Time frame: ICU stay, assessed up to 8 weeks.
Diaphragmatic muscle thickness.
Evaluate the effects of using testosterone cypionate on the diaphragmatic muscle during hospitalization by measuring diaphragm thickness (in millimeters) through ultrasonography.
Time frame: Hospital stay, assessed up to 8 weeks
Diaphragmatic thickening fraction.
Evaluate the effects of using testosterone cypionate on the diaphragmatic muscle during hospitalization through ultrasonography. The thickening fraction is calculated using the following equation: (Final inspiratory diaphragm thickness - Final expiratory diaphragm thickness)/Final expiratory diaphragm thickness × 100. If the result is greater than 36%, it predicts successful weaning from mechanical ventilation.
Time frame: Hospital stay, assessed up to 8 weeks
Skeletal muscle assessment: quadriceps thickness.
Evaluate the effects of using testosterone cypionate on the thickness of the rectus femoris muscle by measuring its thickness at maximum and minimum compression through ultrasonographic analysis.
Time frame: Hospital stay, assessed up to 8 weeks.
Skeletal muscle assessment: Medical Research Council Sum-Score (MRC-SS).
Evaluate the effects of testosterone cypionate on muscle strength gain using the MRC, which scores muscle strength from 0 (no contraction) to 5 (normal muscle contraction) for shoulder flexors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors, totaling 60 points.
Time frame: Hospital stay, assessed up to 8 weeks.
Skeletal muscle assessment: dynamometry.
Evaluate the effects of testosterone on muscle strength gain by measuring handgrip strength using dynamometry with the JAMAR dynamometer.
Time frame: Hospital stay, assessed up to 8 weeks.
Skeletal muscle assessment: calf circumference.
Evaluate the effects of testosterone on muscle mass gain indirectly by measuring calf circumference (in centimeters).
Time frame: Hospital stay, assessed up to 8 weeks.
Functionality and quality of life of critically ill patients during hospital stay: ICU Mobility Scale.
Evaluate the effects of testosterone cypionate use on functionality scores, including the ICU Mobility Scale (IMS) to objectively measure the mobility of patients in the ICU. This scale has a score ranging from 0 to 10, where a score of zero indicates low mobility (interpreted as a patient who only performs passive bed exercises) and a score of 10 indicates high mobility (interpreted as a patient who is independently ambulatory, without assistance).
Time frame: Hospital stay, assessed up to 8 weeks.
Functionality and quality of life of critically ill patients during hospital stay: Perme Intensive Care Unit Mobility Score.
Perme Intensive Care Unit Mobility Score objectively measures the mobility condition of a patient in the ICU. This mobility scale has a score ranging from 0 to 32 points, divided into 15 items grouped into 7 categories: mental state, potential barriers to mobility, functional strength, bed mobility, transfers, assistive devices for ambulation, and endurance measures. In this scale, a higher score indicates greater mobility and less need for assistance. Conversely, a lower score indicates reduced mobility and a greater need for assistance.
Time frame: Hospital stay, assessed up to 8 weeks.
Functionality and quality of life of critically ill patients during hospital stay: FSS-ICU (Functional Status Score for the Intensive Care Unit).
Evaluate the effects of testosterone on the functionality of critically ill patients using the FSS-ICU, a tool that involves five functional tasks (rolling, transferring from supine to sitting, transferring from sitting to standing, sitting on the edge of the bed, and walking). Each task is assessed using an 8-point ordinal scale, ranging from 0 (completely unable to perform) to 7 (complete independence).
Time frame: Hospital stay, assessed up to 8 weeks.
Functionality and quality of life of critically ill patients during hospital stay: TUG (Timed Up and Go).
Evaluate the effects of testosterone cypionate use on functionality scores, including the TUG (Timed Up and Go). The parameter evaluated is the time spent (in seconds) to rise from a chair, walk a distance of 3 meters, and return to sit down. The test is considered normal when the time taken is less than 10 seconds. If the time is between 10 and 19 seconds, the elderly person is considered to have a moderate risk of falling, and this risk increases when the time is 20 seconds or more.
Time frame: Hospital stay, assessed up to 8 weeks.
Correlation of serum testosterone levels, clinical characteristics, and demographics of patients.
Evaluate the correlation between patients clinical and demographic characteristics, as well as free testosterone serum levels in the placebo and intervention groups.
Time frame: Hospital stay, assessed up to 8 weeks.
Correlation with serum levels of hemoglobin and hematocrit, in addition to patients clinical characteristics.
Evaluate the correlation between patients clinical and demographic characteristics and laboratory test levels, about the use of testosterone and the stimulation of erythropoietin production, leading to an increase in red blood cell production and, consequently, an increase in hemoglobin (normal value: 12.5 to 17.2 g/dL) and hematocrit (37-49%).
Time frame: Hospital stay, assessed up to 8 weeks.
Correlation with serum albumin levels and patients clinical characteristics.
Evaluate the correlation between patients clinical and demographic characteristics and laboratory test levels, considering the affinity of total testosterone to albumin (normal value: 3.2 to 4.8 g/dL).
Time frame: Hospital stay, assessed up to 8 weeks.
Functionality and quality of life of critically ill patients during hospital stay: the Barthel Index.
Evaluate the effects of using testosterone cypionate on functionality scores, including the Barthel Index at hospital discharge. The Barthel Index consists of ten items, such as feeding, transferring from bed to chair and back, personal hygiene, using the toilet, bathing, walking on a flat surface, stairs, dressing, fecal continence, and bladder continence. Each item has variable scores ranging from zero to fifteen points, depending on the individuals level of functional dependence. The maximum score is 100, which is assigned only if the patient does not require any assistance.
Time frame: Hospital stay, assessed up to 8 weeks.
Quality of life of critically ill patients during hospital stay: EQ-5D (EuroQol 5-Dimension).
Evaluate the effects of testosterone cypionate use on quality of life, including the EQ-5D (EuroQol 5-Dimension) at hospital discharge. The EQ-5D includes five levels of response for each of the five variables assessed: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each variable is scored from 1 to 5, where 1 indicates no problems and 5 indicates extreme problems. The final score is a combination of the numbers assigned to each variable, resulting in a five-digit code that represents the patients health status.
Time frame: Hospital stay, assessed up to 8 weeks.
Plan to share: Yes — Anonymous participant data will be available upon completion of clinical trials and publication of the results of the completed study upon request to the corresponding author. Proposals will be reviewed and approved by the sponsor, researcher, and staff on the basis of scientific merit and absence of competing interests. After the proposal has been approved, data can only be shared through a secure online platform after data access code exchange and a confidentiality agreement are signed.
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.